TCM
CRSP icon

Tradewinds Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Tradewinds Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$58.5K Hold
1,073
– – 0.01% 197
2026
Q1 		$51K Buy
1,073
+50
+5% +$2.64K 0.01% 216
2025
Q4 		$53.6K Sell
1,023
-370
-27% -$22.2K 0.01% 206
2025
Q3 		$90.3K Hold
1,393
– – 0.02% 154
2025
Q2 		$67.8K Hold
1,393
– – 0.02% 171
2025
Q1 		$47.4K Buy
1,393
+183
+15% +$7.76K 0.01% 196
2024
Q4 		$47.6K Buy
1,210
+100
+9% +$4.72K 0.01% 206
2024
Q3 		$52.1K Hold
1,110
– – 0.01% 185
2024
Q2 		$60K Buy
1,110
+400
+56% +$23.1K 0.02% 161
2024
Q1 		$48.4K Hold
710
– – 0.01% 166
2023
Q4 		$44.4K Hold
710
– – 0.02% 130
2023
Q3 		$32.2K Buy
710
+600
+545% +$31K 0.01% 153
2023
Q2 		$6.18K Hold
110
– – ﹤0.01% 261
2023
Q1 		$4.98K Sell
110
-5
-4% -$243 ﹤0.01% 283
2022
Q4 		$4.67K Hold
115
– – ﹤0.01% 292
2022
Q3 		$8K Buy
115
+5
+5% +$362 ﹤0.01% 218
2022
Q2 		$7K Hold
110
– – ﹤0.01% 235
2022
Q1 		$7K Hold
110
– – ﹤0.01% 517
2021
Q4 		$8K Buy
110
+50
+83% +$4.37K ﹤0.01% 520
2021
Q3 		$7K Hold
60
– – ﹤0.01% 508
2021
Q2 		$10K Hold
60
– – ﹤0.01% 473
2021
Q1 		$7K Hold
60
– – ﹤0.01% 496
2020
Q4 		$9K Hold
60
– – ﹤0.01% 433
2020
Q3 		$5K Hold
60
– – ﹤0.01% 478
2020
Q2 		$4K Hold
60
– – ﹤0.01% 492
2020
Q1 		$3K Sell
60
-15
-20% -$775 ﹤0.01% 497
2019
Q4 		$5K Buy
+75
New +$4.09K ﹤0.01% 496
2019
Q3 		– Sell
-65
Closed -$3K – 615
2019
Q2 		$3K Sell
65
-20
-24% -$799 ﹤0.01% 485
2019
Q1 		$3K Buy
+85
New +$2.94K ﹤0.01% 499

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Tradewinds Capital Management's CRSP Position: Q2 2026 in Review

Tradewinds Capital Management held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 1,073 shares worth $58.5K. The position accounts for 0.01% of the portfolio, ranked #197.

Tradewinds Capital Management first reported a position in CRSP in Q1 2019 and has held it in 29 quarters since. The position peaked at $90.3K in Q3 2025. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Tradewinds Capital Management held 1,073 shares of CRISPR Therapeutics worth $58.5K as of Q2 2026.
  • Tradewinds Capital Management left its CRISPR Therapeutics share count unchanged in Q2 2026.
  • CRISPR Therapeutics made up 0.01% of Tradewinds Capital Management's portfolio in Q2 2026, its #197 holding.
  • Tradewinds Capital Management first reported a position in CRISPR Therapeutics in Q1 2019 and has held it in 29 quarters since.
  • Tradewinds Capital Management's CRISPR Therapeutics position peaked at $90.3K in Q3 2025.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Tradewinds Capital Management's 13F filing for Q2 2026, filed 24 Jul 2026.